Access your copy today:
Three recent studies made it clear: the R2G2® mouse is well suited for preclinical cancer studies that generate PDX, CDX and allograft models.
The R2G2® mouse exhibited reduced radiosensitivity compared to NSGTM mice and tolerated estrogen supplementation and three standard-of-care chemotherapy drugs reasonably well. Moreover, as compared to other traditionally used immunodeficient strains, the R2G2® mouse had higher take rates and more favorable tumor growth.
Based on the findings of these three studies, researchers should feel confident selecting the R2G2® mouse for their next preclinical cancer study.
Download today and understand:
- R2G2® mice responded favorably to estrogen supplementation
- Three standard-of-care chemotherapy drugs were well tolerated in the R2G2® mice
- R2G2® mice had reduced radiosensitivity compared to NSGTM mice
- In some cases, the R2G2® model had higher take rates and better tumor growth date than other immunodeficient strains.